Related Experiment Video
Updated: Nov 15, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Gastrointestinal and hepatic involvement in paediatric systemic lupus erythematosus
Sandra Trapani1, Chiara Rubino2, Gabriele Simonini3
1Meyer Children's University Hospital, Department of Health Sciences, University of Florence, Italy. sandra.trapani@unifi.it.
Insights
Gastrointestinal issues are common in pediatric lupus erythematosus (pSLE), often presenting with non-specific symptoms. Early diagnosis and treatment with immunosuppressants are key for managing these challenging manifestations.
Area of Science:
- Pediatric Rheumatology
- Gastroenterology
- Autoimmune Diseases
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems.
- Gastrointestinal (GI) involvement is well-documented in adult SLE but less understood in pediatric-onset SLE (pSLE).
Purpose of the Study:
- To provide a comprehensive review of GI involvement in pSLE.
- To summarize current knowledge on prevalence, pathogenesis, clinical features, diagnosis, and management of GI issues in pSLE.
Main Methods:
- A narrative review of literature published from 2000 to August 2020.
- Searches conducted on PubMed and EMBASE databases.
Main Results:
- Lupus enteritis is the most common GI manifestation in pSLE, followed by pseudo-obstruction, protein-losing enteropathy, hepatic disease, and pancreatitis.
- Common symptoms include abdominal pain, anorexia, nausea, and vomiting, often alongside other SLE signs.
- Complications like perforation and infarction are life-threatening; early diagnosis and treatment improve outcomes.
Conclusions:
- GI involvement is a frequent and challenging aspect of pSLE.
- Most pSLE GI manifestations respond to glucocorticoids and immunosuppressants.
- Further research is needed to clarify prevalence, prognosis, and optimal treatment strategies.
Abstract:
Systemic lupus erythematosus (SLE) is a multisystemic, autoimmune, inflammatory disease. Gastrointestinal (GI) involvement, extensively described in adults, is less characterised in paediatric-onset SLE (pSLE). The aim of the present narrative review was to provide a comprehensive summary and update on GI involvement in pSLE. A literature search on PubMed and EMBASE was conducted to identify original articles, reviews, case series and editorials published in English from 2000 to 31 August 2020. Based on this, we reported the prevalence, pathogenetic mechanisms, clinical issues, diagnostic tools and management of each form of GI involvement in pSLE. Lupus enteritis is the most frequent type of GI involvement in pSLE, followed by intestinal pseudo-obstruction, protein-losing enteropathy, hepatic disease and acute pancreatitis. The most common presenting GI symptoms are non-specific and include abdominal pain, anorexia, nausea, vomiting. In most cases, they are associated with other clinical and laboratory manifestations of SLE. The complications of GI involvement, including perforation and intestinal infarction, can be life-threatening. Laboratory findings and imaging studies can help to rule out non-SLE related causes for GI manifestations and to reveal typical features of the single forms of GI involvement. Early diagnosis and treatment are crucial to improve prognosis and avoid unnecessary surgery. Most SLE GI manifestations respond well to glucocorticoids and immunosuppressants. In conclusion, GI involvement is frequent in pSLE and its diagnosis and management can be a challenge for clinicians. In view of the limited available data, further studies are needed to better explore the prevalence, prognosis and treatment recommendations for GI involvement in pSLE.
More Related Videos
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacokinetics in Pediatric Patients: Drug Distribution
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...